What's in the serum of seronegative MG and LEMS? MuSK et al

Neurology

Volumn 59, Issue 11, 2002, Pages 1672-1673

  Abicht, Angela ^a   Lochmüller, Hanns ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR;

ANTIBODY DETECTION; BLOOD ANALYSIS; BREATHING MUSCLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EATON LAMBERT SYNDROME; EDITORIAL; EYE DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MEDICAL LITERATURE; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; OPHTHALMOPLEGIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PTOSIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

EID: 0037058803     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000041026.90947.79     Document Type: Editorial

References (13)

1. Plested P, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002;59:1682-1688.
2. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: Study of 110 Japanese patients. Neurology 2002;59:1773-1775.
3. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330: 1797-1810.
4. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
5. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-1059.
6. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252.
7. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: New targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
8. DeChiara TM, Bowen TC, Valenzuela DM, et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996;85:501-512.
9. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann NY Acad Sci 1987;505:326-332.
10. Vincent A, Beeson D, Lang B. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur J Biochem 2000;267:6717-6728.
11. Willcox N, Schluep M, Ritter MA, Newsom-Davis J. The thymus in seronegative myasthenia gravis patients. J Neurol 1991;238:256-261.
12. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium channel antibodies in the Lambert Eaton myasthenic syndrome and other paraneoplastic disorders. N Engl J Med 1995;332:1467-1474.
13. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85-87.